Summary of Provisions in HR 1 Affecting Manufacturers Serving Medicare, Medicaid, CHIP, and the ACA Marketplace
The US House of Representatives passed President Trump’s major domestic agenda bill at 2:30 pm (EDT), Thursday, July 3rd, by a 218-214 vote. The President signed the bill into law during the July 4th events the next day.
Major provisions of the law include an extension of President Trump’s 2017 Tax Cuts, increases in immigration enforcement funding, increases in the debt ceiling, and reductions in federal spending in several key areas.
This policy brief highlights provisions in the law affecting Medicare, Medicaid, CHIP, and the ACA Marketplace. Each table includes a summary of specific provisions, all important dates associated with the provision (i.e., effective dates, etc.), a citation for the provision, and a general statement of how the provision may directly or indirectly affect pharmaceutical manufacturers.
About the Author
Summary of Provisions in HR 1 Affecting Manufacturers Serving Medicare, Medicaid, CHIP, and the ACA Marketplace
HR 1 (2025) is the most significant law affecting Medicare, Medicaid, CHIP, and the ACA marketplace in over a decade. This Summary of the new law, and potential direct and indirect effects on the industry are provided for each provision contained in the law. The Summary also provides an initial assessment on how states will react to the far-ranging policy provisions.
The Year in Medicaid 2024
In this look back at the events of 2024, we recap significant events that shaped Medicaid pharmacy practice.
What the Medicaid Rebate Final Rule Means for Manufacturers
On November 19, 2024, the 2024 Medicaid Rebate Final Rule went into effect. The Final Rule establishes new oversight and enforcement measures for the Medicaid Drug Rebate Program (MDRP), primarily based on the changes introduced by the Medicaid Services Investment and Accountability Act of 2019 (MSIAA).